Pacira Pharma (PCRX) Tops Q2 EPS by 8c ; Offers Guidance

Pacira Pharma (NASDAQ: PCRX) reported Q2 EPS of $0.73, $0.08 better than the analyst estimate of $0.65. Revenue for the quarter came in at $192.4 million versus the consensus estimate of $191.05 million.

GUIDANCE:

Pacira Pharma sees FY2026 revenue of $735-760 million, versus the consensus of $767.8 million.

For earnings history and earnings-related data on Pacira Pharma (PCRX) click here.

You May Also Be Interested In

• Amazon's AWS to acquire DuckLabs, maker of DuckDB database
• Meta to pay $18 billion over 10 years for youth online safety initiatives.
• LightInTheBox Holding (LITB) Reports Q2 EPS of $0.01